Stock Detail
ENTREMED INC
Biotechnology
ENMD @ Yahoo Finance | ENMD Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.73 | $1.78 | $0.06 | 3.59% | 0.00 | $1.67 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.65 | $1.62 | 61,870 | 21.17M | 26,843.5 | -4.44 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.87 | 1.80 | 1.71 | 1.64 | 1.55 |
Stock Profile
EntreMed, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics primarily for the treatment of cancer. It develops multimechanism oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them. The company's lead drug candidate Panzem (2-methoxyestradiol or 2ME2) is in clinical trials for cancer, as well as in preclinical development for nononcology indications. Panzem is in Phase I and Phase II clinical trials. The company also develops various molecules, including analogs of 2ME2, modulators of fibroblast growth factor-2 activity, tissue factor pathway inhibitor peptides, and proteinase activated receptor-2 antagonists to inhibit tumor growth and angiogenesis activities. The company has a strategic alliance with Allergan to develop and commercialize small molecule angiogenic inhibitors for the treatment and prevention of diseases and conditions of the eye; research collaboration with Affymax, Inc. to identify lead tissue factor pathway inhibitor drug candidates for the treatment of cancer; and a cooperative research and development agreement with the National Cancer Institute to evaluate the role of HIF-1alpha inhibition in the treatment of cancer. EntreMed was incorporated in 1991 and is based in Rockville, Maryland.